Drug Development

所在平台: Coursera

课程主页: https://www.coursera.org/learn/drug-development

课程评论:没有评论

第一个写评论        关注课程

课程简介

课程名称:药物开发 概述:加州大学圣迭戈分校斯卡格斯药学与药物科学学院的药物开发课程,通过来自教职员工和行业专家的讲座,分享该领域顶尖人士的独特专业知识。课程将讲解药物开发的不同临床发展阶段及法规要求,包括但不限于研究性新药申请(IND)、新药申请(NDA)以及产品标签。此外,课程还将介绍临床方案设计中如何纳入研究设计方法,以评估安全性、耐受性和多种治疗领域的疗效。 课程内容涵盖临床开发的不同阶段: * 第一阶段(早期临床试验):主要用于确定新药在人类中的作用、安全性以及预测剂量范围,通常涉及30到100名健康志愿者。 * 第二阶段(概念验证研究):测试新药在30到200名患有相关疾病的患者中的疗效、安全性及副作用。 * 第三阶段(后期临床开发):涉及几百到几千名患者,以确定新药是否被认为安全有效,并进行以安慰剂和/或当前治疗作为对照组的研究。 * 产品注册与批准过程:在第三阶段试验确认新药安全有效后,必须在各个国家申请授权,才能投入市场。所有关于小分子或生物制剂的数据需提交至相关国家的监管部门。 本课程是系列课程的第二部分,前一部分为药物发现,后续部分为药物商业化。推荐按顺序修读这些课程,以便更好地理解药物在实验室中的发现过程、临床试验以及最终上市的流程。 课纲简述: 1. 欢迎课程介绍 2. 研究性新药申请的注册考虑因素(讲者:苏珊·特里乌,药学博士) 3. 临床研究与启动活动(讲者:约瑟夫·马,药学博士) 4. 临床试验:第一阶段(讲者:雅兹迪·皮塔瓦拉,博士) 5. 临床试验:第二阶段(讲者:库罗什·帕里瓦尔,药学硕士) 6. 第三阶段临床试验的行业考虑(讲者:凯蒂·莱昂斯,药学博士;凯莉·霍根,药学博士) 7. 新药申请、注册及产品标签(讲者:凯莉·霍根,药学博士)

课程大纲

Name:Welcome!

Description:

Name:Regulatory Considerations When Filing an Investigational New Drug Application, Susan Trieu, Pharm.D.

Description:This week we hear from Dr. Susan Trieu, who in her 12+ years in the industry has worked in regulatory affairs. Since then, Dr. Trieu has gone on to work in Industry at MedImpact as their Drug Information Pharmacist.

Name:Clinical Study & Start-up Activities, Joseph Ma, Pharm.D.

Description:This module is presented by Dr. Joseph Ma, Associate Professor in the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences.

Name:Clinical Trials: Phase 1, Yazdi Pithavala, Ph.D.

Description:This module we will hear from Dr. Yazdi Pithavala, Senior Director, Clinical Pharmacology at Pfizer.

Name:Clinical Trials: Phase 2, Kourosh Parivar, M.Pharm.

Description:Next we hear from Kourosh Parivar, M. Pharm, Vice President & Head, Clinical Pharmacology at Pfizer

Name:Industry Considerations with Phase III Clinical Trials, Katie Lyons, Pharm.D. and Kelly Hogan, Pharm. D.

Description:

Name:New Drug Application, Filing, Product Labeling, Kelly Hogan, Pharm.D.

Description:

课程评论(0条)

课程详情

The University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences Drug Development course brings you lectures from both faculty and industry experts. With this course, recorded on campus at UCSD, we seek to share our access to top people in the field who bring an unprecedented range of expertise on drug development. In this course you will learn the different stages of clinical development as well as the regulatory including but not limited to, an Investigational New Drug Application (IND), New Drug Application (NDA), and product labeling. Additionally you will learn how to Incorporate study design methods for consideration in the design of clinical protocols to assess safety, tolerability, and efficacy in multiple therapeutic areas. In this course you will learn the different phases of clinical development: * Phase 1 or early stage clinical trial are conducted primar­ily to determine how the new drug works in humans, its safety profile and to predict its dosage range. It typically involves between 30 and 100 healthy volunteers. * Phase 2 or Proof of Concept POC studies test for efficacy as well as safety and side effects in a group of between 30 to 200 hundred patients with the disease for which the new drug is being developed. * Phase 3 or late stage clinical development involve much larger group of patients, between a few hundred to thousands, depending on the indication, which will help determine if the new drug can be considered both safe and effective. It will involve control groups using placebo and/or current treatment as a comparison. * Product registration and approval process after a drug is considered safe and effective from Phase 3 trials, it must be authorized in each individual country before it can be marketed. All data gen­erated about the small molecule or biologic is collected and submitted to the regulatory authorities in the US at the FDA, Food and Drug Administration FDA, in Europe the EMA or European Medicines Agency, Japan Ministry of Health and other countries which may require their own national approvals. This course is intended as part 2 of a series: Drug Discovery (https://www.coursera.org/learn/drug-discovery), Drug Development and Drug Commercialization (https://www.coursera.org/learn/drug-commercialization). We would highly recommend that you take the courses in order since it will give you a better understanding on how a drug is discovered in the lab before being tested in clinical trials and then launched in the market place.

课程标签

0人关注该课程

主题相关的课程